Welcome to our dedicated page for Meiragtx Holdings Plc news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings Plc stock.
MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company. Its news flow centers on clinical trial readouts, regulatory designations, strategic collaborations and manufacturing milestones across a broad pipeline in ophthalmology, Parkinson’s disease, radiation-induced xerostomia and other genetic medicine programs.
News updates from MeiraGTx frequently cover progress in late-stage clinical programs such as AAV-AIPL1 for Leber congenital amaurosis 4, AAV2-hAQP1 for radiation-induced xerostomia and AAV-GAD for Parkinson’s disease. The company issues releases on data presented at scientific meetings, including results from randomized, double-blind, sham-controlled studies and first-in-human trials in rare pediatric retinal dystrophies.
Investors and observers can also follow announcements about regulatory interactions, including Regenerative Medicine Advanced Therapy (RMAT) designations, orphan and Rare Pediatric Disease designations, and plans for marketing authorization applications and biologics license applications in the United States, United Kingdom and European Union. These items provide context on potential development pathways for MeiraGTx’s investigational therapies.
Another recurring theme in MeiraGTx news is strategic partnering. The company has reported a collaboration and license agreement with Eli Lilly and Company in ophthalmology, as well as a broad collaboration with Hologen AI that includes the formation of Hologen Neuro AI Ltd to advance AAV-GAD and other central nervous system programs. Updates on its relationship with Johnson & Johnson Innovative Medicine around botaretigene sparoparvovec for X-linked retinitis pigmentosa also appear in its news feed.
In addition, MeiraGTx news items highlight developments in its riboswitch gene regulation platform, promoter and capsid engineering research, and expansions of its GMP manufacturing capabilities in the United Kingdom and Ireland. Visitors to this page can review these releases to understand how MeiraGTx’s clinical, regulatory, technological and manufacturing activities evolve over time.
MeiraGTx Holdings announced its Q3 2022 financial results, reporting a net loss of $37.3 million. The company received a $25 million investment from Johnson & Johnson's innovation arm. Progress in clinical trials includes ongoing dosing for botaretigene sparoparvovec for X-linked Retinitis Pigmentosa and the initiation of a Phase 1 trial for AAV-GAD gene therapy for Parkinson's disease. License revenue decreased to $4.8 million, while research and development expenses decreased to $16.9 million, despite a significant foreign currency loss of $12.8 million.
Summary not available.
MeiraGTx Holdings announced positive results from the Phase 1/2 MGT009 study of botaretigene sparoparvovec for treating X-linked retinitis pigmentosa (XLRP) at the 2022 AAO Annual Meeting. The therapy demonstrated an acceptable safety profile and effective improvements in retinal sensitivity, visual function, and overall vision at six months post-treatment. Currently, the program is progressing to the Phase 3 LUMEOS trial, actively enrolling patients. This therapeutic approach aims to replace a defective gene to restore vision, targeting an unmet need in the XLRP patient population.
MeiraGTx Holdings plc (NASDAQ: MGTX) unveiled its GMP manufacturing facility in Shannon, Ireland, making it the first commercial-scale gene therapy site in the country. Covering 150,000 square feet, the facility integrates viral vector production, plasmid DNA manufacturing, and Quality Control (QC). This development enables accelerated gene therapy treatments for various serious diseases. It aims to reduce clinical development bottlenecks and regulatory risks while cutting costs. The site, employing 100 staff initially, can expand to over 300, supporting collaboration with leading local bioscience institutions.
MeiraGTx Holdings (NASDAQ:MGTX) announced participation in two upcoming investor conferences. CEO Alexandria Forbes will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 3:30 p.m. ET. She will also participate in a panel on Gene Regulation and a subsequent fireside chat at Chardan's 6th Annual Genetic Medicines Conference on October 4, 2022. Live webcasts and replays of the discussions will be available on the company's investor website.
MeiraGTx Holdings plc (MGTX) reported positive topline data from its Phase 1/2 trial of botaretigene sparoparvovec for X-linked retinitis pigmentosa, showing improvements in vision across multiple endpoints. The company secured a financing deal of up to $100 million, extending its cash runway to Q4 2024. Financial results for Q2 2022 revealed license revenue of $10.8 million, up from $5.1 million in Q2 2021. However, the net loss for Q2 2022 was $34 million, significantly higher than the $20.1 million loss in the same period last year.
MeiraGTx Holdings plc (Nasdaq: MGTX) announced a term loan agreement with Perceptive Advisors for up to $100 million, including $75 million immediately available. This minimally dilutive capital, collateralized by manufacturing facilities in London and Shannon, extends the company’s cash runway to Q4 2024. The loan has a 10% interest rate and a maturity date of August 2, 2026. The funds will be used for the development of clinical products and other corporate purposes. The company retains value through its pipeline and manufacturing capabilities, supporting growth in gene therapy.
MeiraGTx Holdings (MGTX) announced positive results from its Phase 1/2 MGT009 clinical study of botaretigene sparoparvovec, an investigational gene therapy for X-linked retinitis pigmentosa (XLRP). The therapy demonstrated a favorable safety profile and significant improvements in retinal function, visual function, and functional vision compared to an untreated control group at six months. The results indicate potential for life-changing impact on patients with XLRP, a condition currently lacking approved treatments. The company is preparing for its Phase 3 Lumeos study while actively enrolling patients.
MeiraGTx Holdings plc (MGTX) reported its Q1 2022 financial results, revealing a license revenue increase to $5.6 million, up from $4.6 million in Q1 2021, mainly due to Janssen collaborations. R&D expenses rose to $23.1 million, reflecting growth in clinical trial costs. The net loss attributable to shareholders was $31 million, compared to $23.6 million a year prior. The company continues to progress its Phase 3 Lumeos trial for X-linked Retinitis Pigmentosa and recently completed the AQUAx study for radiation-induced xerostomia. MeiraGTx maintains a cash reserve of approximately $114 million.
MeiraGTx Holdings announced new clinical data from its Phase 1/2 trial of botaretigene sparoparvovec aimed at treating X-linked Retinitis Pigmentosa (XLRP) at the ARVO 2022 Annual Meeting. Results suggest localized improvements in retinal sensitivity up to 12 months post-treatment. The data indicates that the gene therapy could restore photoreceptor function, with results extending beyond the delivery site. MeiraGTx collaborates with Janssen Pharmaceuticals on this gene therapy, further demonstrating progress in developing treatments for inherited retinal diseases.